Desde 500€ puedes invertir en Biocross a través de Blockchain
the life expectancy and quality of life of individuals with neurodegenerative diseases
through the design of innovative diagnostic systems.
and non-invasive diagnostic tools that can be used
at any stage of the disease.
Early diagnosis
Reliable
Non-invasive
Our goal
To provide neurologists with an integrated diagnostic solution that can be applied to any stage of the disease, including the earliest, asymptomatic phase.
Benefits
- Reduced cost of AD risk-assessment and diagnosis.
- More widespread testing thanks to simpler, more readily available diagnostic methods.
- Improved diagnosis, through earlier detection and differentiation of distinct dementia types.
- Simplified diagnosis through leveraging of existing laboratory equipment.
- Improved patient experience and safety.
The e4Risk® is a non-genetic, cost-effective, and highly reliable method to detect the presence of the ApoE4 protein in human blood plasma using high-throughput chemical analysis.
The AD Dementia test is a multiparametric test that combines the detection and quantification of up to 9 metabolites or proteins in a plasma sample. The input of these measurements into an algorithm provides an accurate diagnosis and classifies the patient as either Alzheimer´s disease or frontotemporal dementia.
The Degenerative dementia test is based on the detection and quantification of up to 7 blood biomarkers that are specifically altered in patients affected by neurodegeneration due to FTD or AD. The DD test is conceived as a “screening” tool for use in clinical practice.
“A la ciencia hay que regarla”
María Llorens, Sergio Veiga y Montse Calleja, en el Café Gijón de Madrid. JAIME VILLANUEVA LA VIDA POR AQUÍ / Juan Cruz - El País, 16 NOV 2019 Decía Margarita Salas que la ciencia lograba hacer "magia" frente a recortes que no dejan respirar. María...
Diseñan un test que detecta factores de riesgo en el desarrollo de alzhéimer
ELISA ÁLVAREZ / SANTIAGO - LA VOZ DE GALICIA 22/10/2018 La epidemia del alzhéimer es imparable. Los estudios más conservadores cifran en medio millón las personas afectadas en España , pero lo más preocupante es su evolución. Cada dos décadas se duplica el número de...
La prueba que pone nombre a los olvidos
E. LERA 28 DE AGOSTO DE 2018 (12:17 H.) - Diario de valladolid La empresa biotecnológica desarrolla nuevos métodos para el diagnóstico de enfermedades neurodegenerativas a través del análisis de muestras de sangre / La «solución integral» se puede aplicar a cualquier...
If you have any questions or comments, we will be pleased to attend you
Avda. Francisco Vallés, 8
47151 Boecillo (Valladolid) - Spain
+34 983 54 98 96
